Mérida, Yucatán.- Clinical trials of the CanSino vaccine against the coronavirus began in Yucatán and will be tested on 2,000 volunteers.
This phase 3 of studies, announced by Governor Mauricio Vila Dosal, is part of a strategic alliance with the Köhler & Milstein Research Institute, focused on the development of biotechnology.
“We will continue with the necessary steps so that the vaccines reach our state as soon as possible for the entire population,” the governor said.
For this, the head of the Yucatan Health Secretariat (SSY), Mauricio Sauri Vivas, and the director of that scientific center, Jesús Abraham Simón, signed a collaboration agreement.
“But it is also a result of the fact that Yucatán has the best doctors in the region and a large number of competent researchers, which confirms the high quality of medical and research personnel that we have, that is, a whole scientific and technological development ecosystem that stands out nationally and internationally ”, said Abraham Simón.
The progressive and free application of the CanSino vaccine, like others of its kind, only considers those over 18 years of age and without serious chronic diseases.
It is a condition to comply with the requirements established in the protocol and there will be a close monitoring for one year for each volunteer, at no cost.
In stage 1 and 2, the formula showed a high safety profile and a robust immune response against the virus, so it is expected that in the next stage it may have an efficacy similar to other vaccines in clinical development, of around 90%. 95 percent.
In preliminary reports, it was reported that there were no serious adverse reactions in any of the volunteers in phase 1 and 2 studies, in addition to the fact that there were no deaths associated with vaccination.
All clinical trials have been approved by ethics, biosafety and research committees, as well as the federal Ministry of Health and the Federal Commission for the Protection of Sanitary Risks (Cofepris), according to the declarants.
In addition, monitoring involves the United States Food and Drug Administration Agency (FDA).